Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study

Introduction: Abemaciclib is an oral, selective small-molecule CDK 4 and 6 inhibitor. In preclinical models, abemaciclib synergized with programmed cell death protein-1 blockade to enhance antitumor efficacy. Here, we report the safety and anticancer activity of abemaciclib plus pembrolizumab in two...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Jean-Louis Pujol, MD, PhD, Johan Vansteenkiste, MD, PhD, Luis Paz-Ares Rodríguez, MD, PhD, Vanesa Gregorc, MD, Julien Mazieres, MD, PhD, Mark Awad, MD, PhD, Pasi A. Jänne, MD, PhD, Michael Chisamore, PhD, Anwar M. Hossain, MStat, Yanyun Chen, PhD, J. Thaddeus Beck, MD, FACP
Format: article
Langue:EN
Publié: Elsevier 2021
Sujets:
Abemaciclib
KRAS-mutant
PD-L1 positive non–small cell lung cancer
Pembrolizumab
Squamous
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/c9caff189596499fa7e9767a030f2c97
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/c9caff189596499fa7e9767a030f2c97

Documents similaires